Seqera
Seqera makes scientific data analysis accessible at any scale. It develops open-science software and enterprise services that let life-science teams build, run, monitor, reproduce and scale data-intensive workflows across cloud, HPC and on-premises infrastructure.
At a Glance
- Pharmaceutical companies
- Biotechnology companies
- Clinical diagnostics
- Academic and public research institutions
- +3 more
AI Tools by Seqera
(1)
Nextflow
Open Source Data Pipeline Workflow
Discussions
No discussions yet
Be the first to start a discussion about Seqera
Latest News
Seqera raises $26M Series B led by Addition, with Speedinvest, Talis, Amino Collective, BoxOne and SNR participating.
Seqera Compute launches public preview for managed, optimized compute for scalable bioinformatics.
Seqera Studios becomes generally available for reproducible interactive analysis.
Seqera AI in Platform launches for unified workflow development, debugging and execution.
Products & Services
Open-source workflow orchestrator and DSL for scalable, portable and reproducible scientific pipelines across local machines, HPC, cloud and serverless environments.
Enterprise platform for developing, launching, monitoring and governing Nextflow pipelines, data, compute and collaborative analysis across cloud, hybrid and on-premises deployments.
Containerized, reproducible interactive analysis environments with managed sessions, snapshots, cloud-storage access, credentials and collaboration.
AI assistance available through UI, CLI and MCP for pipeline development, launch, debugging, data interpretation and autonomous workflow agents.
Market Position
Seqera positions itself as a Nextflow-first, open-science alternative to fragmented workflow, data and compute tooling: it combines a widely adopted open-source orchestrator with enterprise pipeline management, data governance, interactive analysis, AI assistance, container provisioning and optimized compute. Its differentiation is portability across cloud/HPC/on-premises, reproducibility, data sovereignty and an open community ecosystem. Relevant competing categories include workflow/orchestration platforms such as Cromwell/ Terra, Galaxy, WDL/Cromwell-based stacks, Snakemake and Airflow, plus cloud-native bioinformatics platforms from AWS, Google Cloud and Microsoft Azure.
Leadership
Founders
Paolo Di Tommaso
Bioinformatics and computational-biology researcher at Barcelona's Centre for Genomic Regulation (CRG); creator of Nextflow and Seqera's Chief Architect (formerly described as CTO).
Evan Floden
Computational biologist, PhD researcher in CRG's Comparative Bioinformatics group and former Wellcome Trust Sanger Institute researcher; founding Nextflow contributor and Seqera CEO.
Executive Team
Evan Floden
CEO & Co-Founder
Computational biologist and founding Nextflow contributor; previously worked in CRG's Comparative Bioinformatics group and at the Wellcome Trust Sanger Institute.
Paolo Di Tommaso
Chief Architect & Co-Founder
Bioinformatics researcher at CRG and creator of Nextflow.
Board of Directors
Founding Story
Nextflow began at CRG in 2013 when Di Tommaso and Floden sought an open, scalable and reproducible way to run complex biological analyses across fragmented computing environments. Seqera launched as a CRG spin-off in 2018 (publicly announced in 2019) to commercialize enterprise-grade software, support and services around the Nextflow stack while strengthening its open-source community.
Business Model
Revenue Model
Commercial subscriptions and usage-based cloud/compute charges for Seqera Platform, plus enterprise licensing/deployment and professional services such as implementation, consulting, training and support. Nextflow, Wave and MultiQC are open-source/free software that expand the commercial platform ecosystem.
Pricing Tiers
Up to 3 users, 3 concurrent runs, 250-run history, 100 datasets with 10 MB size, 100 versions and 100 vCPUs of managed compute.
For R&D teams; unlimited concurrent runs and run history, with expanded Co-Scientist and compute capacity.
For strict IT/security requirements, including fine-grained access controls, identity integration, SSO, audit logging and enterprise deployment.
For clinical and manufacturing use cases needing GxP validation and 21 CFR Part 11/EU Annex 11-oriented controls.
No upfront commitments or minimum spend; network is pass-through provider cost.
Target Markets
- Pharmaceutical companies
- Biotechnology companies
- Clinical diagnostics
- Academic and public research institutions
- Healthcare and public-health organizations
- Agriculture
- Genomics and sequencing
- Clinical diagnostics and genomic surveillance
- Drug discovery and biopharma R&D
- Personalized medicine and oncology
- Protein analysis and structure prediction
- Image processing and high-throughput biology
- AstraZeneca
- Roche
- Moderna
- Oxford Nanopore